MX2020008445A - Metodos para tratar el cancer con anticuerpos anti-pd-1. - Google Patents
Metodos para tratar el cancer con anticuerpos anti-pd-1.Info
- Publication number
- MX2020008445A MX2020008445A MX2020008445A MX2020008445A MX2020008445A MX 2020008445 A MX2020008445 A MX 2020008445A MX 2020008445 A MX2020008445 A MX 2020008445A MX 2020008445 A MX2020008445 A MX 2020008445A MX 2020008445 A MX2020008445 A MX 2020008445A
- Authority
- MX
- Mexico
- Prior art keywords
- treating cancer
- methods
- binding fragment
- antibodies
- antibody
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Abstract
La presente invención se relaciona con métodos para tratar cáncer en un paciente que comprende administrar un antagonista de PD-1, por ejemplo, un anticuerpo de anti-PD-1 o un fragmento de unión a antígeno del mismo (por ejemplo, pembrolizumab), en cantidades específicas al paciente aproximadamente cada seis semanas. En algunas modalidades, la cantidad del anticuerpo de anti-PD-1 o un fragmento de unión a antígeno del mismo es aproximadamente 400 mg. En ciertas modalidades, el antagonista de PD-1 es pembrolizumab o un fragmento de unión a antígeno del mismo. También se proporcionan las composiciones y kits que comprenden una dosis de un anticuerpo de anti-PD-1 o un fragmento de unión a antígeno del mismo y los usos del mismo para tratar cáncer.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862630038P | 2018-02-13 | 2018-02-13 | |
US201862732828P | 2018-09-18 | 2018-09-18 | |
PCT/US2019/017177 WO2019160751A2 (en) | 2018-02-13 | 2019-02-08 | Methods for treating cancer with anti-pd-1 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020008445A true MX2020008445A (es) | 2020-09-28 |
Family
ID=67620026
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020008445A MX2020008445A (es) | 2018-02-13 | 2019-02-08 | Metodos para tratar el cancer con anticuerpos anti-pd-1. |
Country Status (15)
Country | Link |
---|---|
US (2) | US20210047408A1 (es) |
EP (1) | EP3752180A4 (es) |
JP (2) | JP2021513541A (es) |
KR (1) | KR20200119844A (es) |
CN (1) | CN111712255A (es) |
AU (1) | AU2019220495A1 (es) |
BR (1) | BR112020016331A8 (es) |
CA (1) | CA3090995A1 (es) |
CL (1) | CL2020002075A1 (es) |
IL (1) | IL276303A (es) |
MA (1) | MA52789A (es) |
MX (1) | MX2020008445A (es) |
RU (1) | RU2020129827A (es) |
SG (1) | SG11202007590TA (es) |
WO (1) | WO2019160751A2 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2170959T3 (da) | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
WO2021061719A1 (en) | 2019-09-27 | 2021-04-01 | Merck Sharp & Dohme Corp. | Methods for treating metastatic triple negative breast cancer with anti-pd-1 antibodies |
WO2021123202A1 (en) | 2019-12-20 | 2021-06-24 | Formycon Ag | Formulations of anti-pd1 antibodies |
US20230050449A1 (en) * | 2019-12-20 | 2023-02-16 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
CN112326961B (zh) * | 2020-10-30 | 2021-08-06 | 福州迈新生物技术开发有限公司 | 一种非小细胞肺癌中pd-l1阳性肿瘤细胞比例的分析方法和存储设备 |
CN112394102B (zh) * | 2020-11-05 | 2023-05-26 | 上海交通大学医学院附属瑞金医院 | 一种检测垂体功能减退症的标志物及其应用 |
KR20240024941A (ko) | 2021-06-23 | 2024-02-26 | 포르미콘 아게 | 항-pd1 항체의 제제 |
WO2023003790A1 (en) * | 2021-07-20 | 2023-01-26 | Merck Sharp & Dohme Llc | Methods for treating cancer using a combination of a pd-1 antagonist, an ilt4 antagonist, and chemotherapeutic agents |
CN113893343A (zh) * | 2021-10-16 | 2022-01-07 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗***患者的药物中的用途 |
WO2023114346A2 (en) * | 2021-12-16 | 2023-06-22 | Merck Sharp & Dohme Llc | Biomarkers for predicting eligibility for an anti-ilt4 and anti-pd-1 combination therapy |
CN115925954A (zh) * | 2022-12-28 | 2023-04-07 | 广州誉衡生物科技有限公司 | 抗-pd-1抗体及其在制备治疗尿路上皮癌患者的药物中的用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK2170959T3 (da) * | 2007-06-18 | 2014-01-13 | Merck Sharp & Dohme | Antistoffer mod human programmeret dødsreceptor pd-1 |
CN103429264A (zh) | 2011-03-31 | 2013-12-04 | 默沙东公司 | 针对人程序性死亡受体pd-1的抗体的稳定制剂和有关的治疗 |
AU2015289533B2 (en) | 2014-07-18 | 2021-04-01 | Advaxis, Inc. | Combination of a PD-1 antagonist and a Listeria-based vaccine for treating prostate cancer |
US10695426B2 (en) * | 2014-08-25 | 2020-06-30 | Pfizer Inc. | Combination of a PD-1 antagonist and an ALK inhibitor for treating cancer |
KR20210069124A (ko) | 2014-11-13 | 2021-06-10 | 더 존스 홉킨스 유니버시티 | 관문 차단 및 미소부수체 불안정성 |
AR103726A1 (es) * | 2015-02-27 | 2017-05-31 | Merck Sharp & Dohme | Cristales de anticuerpos monoclonales anti-pd-1 humanos |
WO2016176504A1 (en) | 2015-04-28 | 2016-11-03 | Bristol-Myers Squibb Company | Treatment of pd-l1-positive melanoma using an anti-pd-1 antibody |
WO2017165125A1 (en) * | 2016-03-24 | 2017-09-28 | Millennium Pharmaceuticals, Inc. | Use of a pd-1 antagonist and an anti-ccr2 antibody in the treatment of cancer |
EP3464369A1 (en) * | 2016-06-03 | 2019-04-10 | Bristol-Myers Squibb Company | Anti-pd-1 antibody for use in a method of treating a tumor |
KR20200014363A (ko) * | 2017-06-01 | 2020-02-10 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체를 사용하여 종양을 치료하는 방법 |
-
2019
- 2019-02-08 JP JP2020542960A patent/JP2021513541A/ja active Pending
- 2019-02-08 WO PCT/US2019/017177 patent/WO2019160751A2/en unknown
- 2019-02-08 SG SG11202007590TA patent/SG11202007590TA/en unknown
- 2019-02-08 MX MX2020008445A patent/MX2020008445A/es unknown
- 2019-02-08 CN CN201980013286.8A patent/CN111712255A/zh active Pending
- 2019-02-08 RU RU2020129827A patent/RU2020129827A/ru unknown
- 2019-02-08 US US16/966,968 patent/US20210047408A1/en active Pending
- 2019-02-08 BR BR112020016331A patent/BR112020016331A8/pt unknown
- 2019-02-08 MA MA052789A patent/MA52789A/fr unknown
- 2019-02-08 EP EP19754909.0A patent/EP3752180A4/en active Pending
- 2019-02-08 KR KR1020207026004A patent/KR20200119844A/ko unknown
- 2019-02-08 AU AU2019220495A patent/AU2019220495A1/en active Pending
- 2019-02-08 CA CA3090995A patent/CA3090995A1/en active Pending
-
2020
- 2020-07-26 IL IL276303A patent/IL276303A/en unknown
- 2020-08-10 CL CL2020002075A patent/CL2020002075A1/es unknown
-
2023
- 2023-09-01 US US18/459,842 patent/US20240026003A1/en active Pending
-
2024
- 2024-01-04 JP JP2024000162A patent/JP2024038251A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
SG11202007590TA (en) | 2020-09-29 |
CL2020002075A1 (es) | 2020-10-23 |
JP2024038251A (ja) | 2024-03-19 |
EP3752180A2 (en) | 2020-12-23 |
MA52789A (fr) | 2021-04-14 |
AU2019220495A1 (en) | 2020-08-13 |
JP2021513541A (ja) | 2021-05-27 |
US20240026003A1 (en) | 2024-01-25 |
EP3752180A4 (en) | 2021-12-15 |
RU2020129827A (ru) | 2022-03-14 |
BR112020016331A8 (pt) | 2023-02-07 |
US20210047408A1 (en) | 2021-02-18 |
WO2019160751A2 (en) | 2019-08-22 |
WO2019160751A3 (en) | 2020-09-10 |
CN111712255A (zh) | 2020-09-25 |
BR112020016331A2 (pt) | 2020-12-15 |
IL276303A (en) | 2020-09-30 |
KR20200119844A (ko) | 2020-10-20 |
CA3090995A1 (en) | 2019-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020008445A (es) | Metodos para tratar el cancer con anticuerpos anti-pd-1. | |
MX2020008446A (es) | Metodos para el tratamiento contra el cancer mediante anticuerpos anti-pd-1 y anticuerpos anti-ctla4. | |
PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
EA201891428A1 (ru) | Комбинация антител к pd-1 и биспецифических антител к cd20/cd3 для лечения злокачественной опухоли | |
EA201992590A1 (ru) | Стабильные композиции антител к рецептору программируемой гибели 1 (pd-1) и способы их применения | |
EA201490957A1 (ru) | Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела | |
EA201992526A1 (ru) | Стабильные составы анти-ctla4 антител, отдельно и в комбинации с антителами против рецептора 1 программируемой смерти (pd-1), и способы их применения | |
MX2020008736A (es) | Formulaciones de anticuerpos b7-h4. | |
MX2020010913A (es) | Anticuerpos anti-cd27 y anti-pd-l1 y constructos biespecíficos. | |
MX2020012567A (es) | Anticuerpos anti-ox40 y metodos de uso. | |
EA201990374A1 (ru) | Комбинация антитела против cd20, ингибитора pi3-киназы-дельта и антитела против pd-1 или против pd-l1 для лечения гематологических раков | |
MX2020012613A (es) | Composiciones y usos de las mismas para el tratamiento de enfermedades o afecciones. | |
MX2021009041A (es) | Anticuerpo anti-pd-1, fragmento de union a antigeno del mismo y uso farmaceutico del mismo. | |
MX2021010116A (es) | Anticuerpo anti-pd-l1 y uso de este. | |
MX2021004226A (es) | Terapia combinada contra el cáncer. | |
MX2023004399A (es) | Tratamiento de combinacion. | |
MX2022001403A (es) | Metodos de administracion de anticuerpos anti-siglec-8 y corticosteroides. | |
MX2021003673A (es) | Anticuerpos anti-vsig4 humano y usos de los mismos. | |
MX2021006362A (es) | Anticuerpos de dominio simple contra cll-1. | |
EA202192587A1 (ru) | Антитела к cd73, антитела к pd-l1 и химиотерапия для лечения опухолей | |
PH12020551454A1 (en) | Anti-cd25 for tumour specific cell depletion | |
MX2022006728A (es) | Metodos y combinaciones para el tratamiento del cancer utilizando anticuerpos inhibidores de puntos de control inmunitario. | |
MX2022001411A (es) | Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5. | |
CR20230473A (es) | Métodos para el tratamiento del cáncer con administración subcutánea de anticuerpos anti-pd1. | |
PH12019550203A1 (en) | Erbb-2 targeting agent and a bispecific antibody with antigen-binding sites that bind an epitope on an extracellular part of erb-2 and erbb-3, for treatment of an individual with an erbb-2, erbb-2/erbb-3 positive tumour |